Dr. Buzdar begins this chapter with an explanation of why ethical review boards (the first IRBs) were established after the Second World War. MD Anderson was in the forefront of the movement, and established the first ethics committee in 1966. Dr. Buzdar served on the IRB for a decade. Dr. Buzdar then talks about the power of the IRB, which operates as an independent and final authority in determining whether a protocol can proceed. He gives an example of immunotherapy trials using CAR T cells [chimeric antigen receptor T cells], a treatment that has very serious side effects, leading in some cases to death. Dr. Buzdar describes the unique (in the nation) initiative that MD Anderson has undertaken to monitor and treat these patients fo...
In this chapter, Dr. Dmitrovsky provides an overview of how MD Anderson must operate in the new envi...
Dr. Bast begins this chapter by noting that, in the mid-seventies he wrote a review of research on B...
Dr. Roth begins this chapter by discussing gene studies he initiated at MD Anderson, the first one f...
Dr. Buzdar begins this chapter with an explanation of why ethical review boards (the first IRBs) wer...
Dr. Elting begins this chapter by reviewing the proliferation of IRBs at MD Anderson. She discusses...
Dr. Elting sketching her role in MD Anderson’s Institutional Review Boards, including establishing a...
In this chapter, Dr. Buzdar talks about his role as Vice President of Clinical Research, an office t...
In this chapter, Dr. Gehan talks about Dr. Jan VanEys’ work in pediatrics and as an ethicist at MD A...
Dr. Freireich explains why the slow evolution of the blood separator made it necessary for him to le...
Dr. Ewer begins this chapter by explaining that in the early eighties, as a result of his work in in...
In this chapter, Dr. Elting responds to the observation that many researchers have an adversarial vi...
Dr. Buzdar first sets his philosophy of clinical research in the context of his early work on aggres...
In this segment, Dr. Rodriguez describes studies she conducted on lymphoma treatments in collaborati...
Dr. Ewer begins this chapter by stressing that MD Anderson has always been interested in ‘doing the ...
In this chapter, Dr. Buzdar explains the function of the Committee on Drug Side Effect, created six ...
In this chapter, Dr. Dmitrovsky provides an overview of how MD Anderson must operate in the new envi...
Dr. Bast begins this chapter by noting that, in the mid-seventies he wrote a review of research on B...
Dr. Roth begins this chapter by discussing gene studies he initiated at MD Anderson, the first one f...
Dr. Buzdar begins this chapter with an explanation of why ethical review boards (the first IRBs) wer...
Dr. Elting begins this chapter by reviewing the proliferation of IRBs at MD Anderson. She discusses...
Dr. Elting sketching her role in MD Anderson’s Institutional Review Boards, including establishing a...
In this chapter, Dr. Buzdar talks about his role as Vice President of Clinical Research, an office t...
In this chapter, Dr. Gehan talks about Dr. Jan VanEys’ work in pediatrics and as an ethicist at MD A...
Dr. Freireich explains why the slow evolution of the blood separator made it necessary for him to le...
Dr. Ewer begins this chapter by explaining that in the early eighties, as a result of his work in in...
In this chapter, Dr. Elting responds to the observation that many researchers have an adversarial vi...
Dr. Buzdar first sets his philosophy of clinical research in the context of his early work on aggres...
In this segment, Dr. Rodriguez describes studies she conducted on lymphoma treatments in collaborati...
Dr. Ewer begins this chapter by stressing that MD Anderson has always been interested in ‘doing the ...
In this chapter, Dr. Buzdar explains the function of the Committee on Drug Side Effect, created six ...
In this chapter, Dr. Dmitrovsky provides an overview of how MD Anderson must operate in the new envi...
Dr. Bast begins this chapter by noting that, in the mid-seventies he wrote a review of research on B...
Dr. Roth begins this chapter by discussing gene studies he initiated at MD Anderson, the first one f...